Updated April 2026 · CMS & FDA public data
Drug Pricing Blog
Data-driven analysis of prescription drug costs, powered by the CMS Medicare Part D Drug Spending Dashboard, the FDA Orange Book, and CMS Inflation Reduction Act negotiation announcements. Every claim is sourced; no manufacturer or PBM sponsorship.
What the DrugPrice Blog Covers
U.S. prescription drug coverage is built on confusing layers — wholesale list prices, PBM rebates, formularies, copay cards, manufacturer assistance programs, Medicare Part D, the IRA negotiation list, the new $2,000 out-of-pocket cap, biosimilars, the patent cliff, and the rapid expansion of cash-pay channels like Mark Cuban Cost Plus Drugs and Amazon Pharmacy. Each piece moves the price you actually pay at the counter, and they interact in ways that are not obvious from a copay card or a single insurance EOB.
The blog organizes this into four threads: explainers (how the system works), policy (what is changing), comparisons (which channel saves you the most for a given drug), and rankings drawn directly from CMS spending data. Articles are written from public records, dated, and re-checked against the underlying datasets on each refresh cycle.
Guide
Long-form, evergreen reference. Built to be the most thorough single page on the topic, with worked examples and source links.
How Drug Pricing Works in America: The Complete Guide
The definitive guide to WAC, AWP, NADAC, PBMs, and the entire drug pricing supply chain. Understand why your prescription costs what it does.
GLP-1 Pricing Guide 2026: Ozempic vs Wegovy vs Mounjaro vs Zepbound
Compare costs for every GLP-1 drug. Medicare negotiated prices, compounded alternatives, TrumpRx discounts, and how to save.
The Cheapest Prescription Drugs by Class: A Complete Price Guide
Find the lowest-cost option for statins, blood pressure meds, antidepressants, diabetes drugs, and more.
Biosimilars Explained: The Generic Revolution for Biologic Drugs
What biosimilars are, how they save money, and the current landscape: 22 Humira biosimilars, 9 Stelara biosimilars, and more.
Comparison
Side-by-side breakdown of competing options — discount programs, drug classes, formulations — using real CMS pricing data rather than marketing claims.
Policy
How federal and state rules — Inflation Reduction Act negotiation, biosimilar pathways, 340B, exclusivity windows — actually move pharmacy-counter prices.
Analysis
Data analysis using CMS Medicare Part D and FDA Orange Book records, looking for patterns the headline coverage misses.
The Patent Cliff: $230 Billion in Drug Savings Coming by 2030
Major drugs losing patent protection 2025-2030. When generics launch for Januvia, Eliquis, Keytruda, and more.
PBM Transparency: Where Your Drug Dollar Goes
How pharmacy benefit managers control 80% of prescriptions, profit from spread pricing, and why reform is coming in 2028.
Why Drug Prices Keep Going Up: A Data Breakdown
Drugs with the biggest year-over-year price increases and the systemic reasons behind rising prescription costs.
Ranking
Ranked tables drawn directly from public CMS spending data — not editorial picks, not sponsored placements.
Data
Reference data tables, refreshed against the underlying federal dataset on each update cycle.
How These Articles Are Researched
Every spending number, ranking, and patent date links back to a public federal dataset. Cost-per-claim and total spending come from the CMS Medicare Part D Drug Spending Dashboard. Acquisition cost benchmarks come from CMS NADAC. Patent expirations and generic launches come from the FDA Orange Book. The full DrugPrice methodology documents the data joins and refresh cadence.
Frequently Asked Questions
Where do these articles get their numbers?
Every dollar figure on DrugPrice traces to a public federal dataset. Average cost-per-claim, top spending drugs, and year-over-year changes come from the CMS Medicare Part D Drug Spending Dashboard. Patent expirations and generic approval dates come from the FDA Orange Book. Negotiated Medicare prices come straight from CMS's Inflation Reduction Act announcements. We do not estimate, model, or use industry-supplied numbers. Last refreshed April 2026.
How often are the articles updated?
The CMS Part D dataset is released annually, typically each fall, and we re-run every spending and ranking article against the new file when it ships. The Orange Book updates monthly, so the patent-cliff and generic-launch articles are revised when material changes occur. Each article carries a published date and any update notes; the master refresh date is April 2026.
Is DrugPrice giving medical advice?
No. DrugPrice describes what the public pricing data shows. It does not recommend a specific drug, switch a generic for a brand, suggest stopping or starting a treatment, or substitute for a conversation with your prescriber and pharmacist. If an article flags a cheaper clinically equivalent option (for example, a generic statin versus a brand statin), treat that as input for a clinical conversation, not a clinical recommendation.
Why are some drugs so much more expensive than others?
Three forces dominate U.S. drug pricing: market exclusivity (patents, FDA exclusivity windows, regulatory barriers to generic entry), the rebate flow between manufacturers and pharmacy benefit managers (PBMs), and the lack of a single national price negotiator before the Inflation Reduction Act. The articles tagged "Analysis" and "Policy" walk through each of these forces using specific drug examples.
How do I actually pay less at the pharmacy?
There is no universal cheapest channel — the right answer depends on the drug, your insurance, and whether the drug is generic. The "TrumpRx vs GoodRx vs Cost Plus Drugs" comparison and the "Cheapest Drugs by Class" guide give a concrete decision flow. For most generic maintenance medications, mail-order pharmacies like Mark Cuban Cost Plus Drugs and Amazon Pharmacy are typically lowest. For brand drugs with manufacturer copay cards, the manufacturer program usually beats discount cards. For Medicare beneficiaries, the new $2,000 annual out-of-pocket cap (effective 2025) reshapes which strategy pays off.
Sources: CMS Medicare Part D Drug Spending Dashboard, CMS NADAC, FDA Orange Book, openFDA, HHS Office of the Inspector General. All data is U.S. government public domain. Cite as: "DrugPrice, April 2026 reading. Data: CMS Part D & FDA."
Last updated 2026-04-06 · 11 articles published.